WO2005123115A8 - Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants - Google Patents

Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants

Info

Publication number
WO2005123115A8
WO2005123115A8 PCT/AU2005/000856 AU2005000856W WO2005123115A8 WO 2005123115 A8 WO2005123115 A8 WO 2005123115A8 AU 2005000856 W AU2005000856 W AU 2005000856W WO 2005123115 A8 WO2005123115 A8 WO 2005123115A8
Authority
WO
WIPO (PCT)
Prior art keywords
sphingosine kinase
present
modulating
agents
cellular activity
Prior art date
Application number
PCT/AU2005/000856
Other languages
French (fr)
Other versions
WO2005123115A1 (en
Inventor
Stuart M Pitson
Mathew Alexander Vadas
Pu Xia
Paul A Moretti
Tamara Leclercq
Catherine Sutherland
Original Assignee
Medvet Science Pty Ltd
Stuart M Pitson
Mathew Alexander Vadas
Pu Xia
Paul A Moretti
Tamara Leclercq
Catherine Sutherland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004903249A external-priority patent/AU2004903249A0/en
Application filed by Medvet Science Pty Ltd, Stuart M Pitson, Mathew Alexander Vadas, Pu Xia, Paul A Moretti, Tamara Leclercq, Catherine Sutherland filed Critical Medvet Science Pty Ltd
Priority to AU2005253643A priority Critical patent/AU2005253643B2/en
Priority to CA002569687A priority patent/CA2569687A1/en
Priority to JP2007515736A priority patent/JP2008502604A/en
Priority to MXPA06014888A priority patent/MXPA06014888A/en
Priority to EP05750186A priority patent/EP1765384A4/en
Publication of WO2005123115A1 publication Critical patent/WO2005123115A1/en
Publication of WO2005123115A8 publication Critical patent/WO2005123115A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates generally to a method of modulating cellular activity and to agents for use therein. More particularly, the present invention provides a method of modulating cellular activity by modulating intracellular translocation of sphingosine kinase to the cell membrane. In a related aspect, the present invention provides a method of modulating sphingosine kinase mediated signalling via modulation of its intracellular translocation and agents for use therein. The present invention still further extends to sphingosine kinase variants and to functional derivatives, homologues and analogues thereof, exhibiting ablated or reduced capacity to undergo translocation. The method and molecules of the present invention are useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate cellular functional activity and/or aberrant, unwanted or otherwise inappropriate sphingosine kinase mediated signalling. The present invention is further directed to methods for identifying and/or designing agents capable of modulating sphingosine kinase intracellular translocation.
PCT/AU2005/000856 2004-06-15 2005-06-15 Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants WO2005123115A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2005253643A AU2005253643B2 (en) 2004-06-15 2005-06-15 Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
CA002569687A CA2569687A1 (en) 2004-06-15 2005-06-15 Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
JP2007515736A JP2008502604A (en) 2004-06-15 2005-06-15 Methods for modulating cellular activity, including sphingosine kinase, substances for modulating, and sphingosine kinase variants
MXPA06014888A MXPA06014888A (en) 2004-06-15 2005-06-15 Method of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants.
EP05750186A EP1765384A4 (en) 2004-06-15 2005-06-15 Method of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004903249 2004-06-15
AU2004903249A AU2004903249A0 (en) 2004-06-15 A method of modulating cellular activity and agents useful for same

Publications (2)

Publication Number Publication Date
WO2005123115A1 WO2005123115A1 (en) 2005-12-29
WO2005123115A8 true WO2005123115A8 (en) 2006-04-20

Family

ID=35509458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2005/000856 WO2005123115A1 (en) 2004-06-15 2005-06-15 Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants

Country Status (5)

Country Link
EP (1) EP1765384A4 (en)
JP (1) JP2008502604A (en)
CA (1) CA2569687A1 (en)
MX (1) MXPA06014888A (en)
WO (1) WO2005123115A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
JP2005502598A (en) * 2001-06-07 2005-01-27 メドベット・サイエンス・プロプライエタリー・リミテッド Methods of treatment by regulating cytokine-mediated cellular activity and substances useful therefor
AU2003215426A1 (en) * 2002-03-28 2003-10-13 Medvet Science Pty. Ltd. A method of modulating cellular activity

Also Published As

Publication number Publication date
WO2005123115A1 (en) 2005-12-29
MXPA06014888A (en) 2007-03-21
JP2008502604A (en) 2008-01-31
EP1765384A1 (en) 2007-03-28
CA2569687A1 (en) 2005-12-29
EP1765384A4 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
UA95244C2 (en) Compounds and methods for kinase modulation, and indications therefor
WO2004010894A3 (en) Ophthalmologic irrigation solutions and method
WO2005067546A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2007024971A3 (en) Hedgehog pathway antagonists to treat disease
WO2005060396A3 (en) Nanotopographic compositions and methods for cellular organization in tissue engineered structures
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
NO20063572L (en) Quinazoline dithosylate salt compounds
SI1631295T1 (en) Use of condensed heterocyclic compounds as scce inhibitors for the treatment of skin diseases
WO2008063888A3 (en) Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2007103826A3 (en) Bone prosthesis
WO2006128142A3 (en) Inhibitors of cytosolic phospholipase a2
WO2007021590A3 (en) Topographical templating of polymeric materials using cellular morphology
WO2003020297A3 (en) Method of improving wound healing
WO2003024386A8 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
WO2004053101A3 (en) Methods and compositions using compounds from fetal cells and tissues to improve condition of skin
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
WO2004053069A3 (en) PROTECTION OF STEM CELLS FROM CYTOTOXIC AGENTS BY MODULATION OF β-CATENIN SIGNALING PATHWAYS
WO2005117968A3 (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
WO2005023305A3 (en) Modulating cell activity by using an agent that reduces the level of cholesterol within a cell
EP1742643A4 (en) MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOCASE EXPRESSION
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
WO2007025064A3 (en) METHODS OF USING SELECTIVE llβ-HSD INHIBITORS TO TREAT GLUOCORTICOID ASSOCIATED STATES
WO2005123115A8 (en) Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
WO2004097009A3 (en) METHOD TO IDENTIFY AGENTS THAT ACTIVATE OR INHIBIT IKKi
WO2008027379A3 (en) Indicators of sirtuin activity and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

WWE Wipo information: entry into national phase

Ref document number: 2005253643

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005253643

Country of ref document: AU

Date of ref document: 20050615

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005253643

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2569687

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 551935

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/014888

Country of ref document: MX

Ref document number: 2007515736

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005750186

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005750186

Country of ref document: EP